The neuropeptide somatostatin (SST) regulates amyloid β peptide (Aβ) catabolism by
enhancing neprilysin (NEP)-catalyzed proteolytic degradation. However, the mechanism by …

Alzheimer's disease (AD) is characterized by the deposition of amyloid β peptide (Aβ) in the
brain. The neuropeptide somatostatin (SST) regulates Aβ catabolism by enhancing …

Alzheimer's disease is the most common neurodegenerative disorder characterized by the
pathological aggregation of amyloid-β (Aβ) peptide. A potential therapeutic intervention in …

Alzheimer's disease (AD) brains are characterized by increased levels of the pathogenic
amyloid beta (Aβ) peptide, which accumulates into extracellular plaques. Finding a way to …

The molecular underpinnings that govern the endoproteolytic release of the amyloid beta
peptide (Aβ) from the amyloid precursor protein (APP) are now quite well understood. The …

The neuroendocrine peptide somatostatin (SST) has long been thought of as influencing the
deposition of the amyloid β peptide (Aβ) in Alzheimer's disease (AD). Missing have been in …

Alzheimer's disease (AD) is a neurodegenerative disease displaying extracellular plaques
formed by the neurotoxic amyloid β‐peptide (Aβ), and intracellular neurofibrillary tangles …

Background Aggregation of the amyloid-β (Aβ) peptide in the brain is one of the key
pathological events in Alzheimer's disease (AD). Reducing Aβ levels in the brain by …

Alzheimer's disease is associated with the deposition of extracellular senile plaques, made
primarily of amyloid-β (Aβ), particularly peptides Aβ1–42 and Aβ1–40. Neprilysin, or neutral …

Amyloid-beta (Aβ) peptide accumulation in the brain is a pathological hallmark of all forms of
Alzheimer's disease. An imbalance between Aβ production and clearance from the brain …